期刊文献+

程序性死亡因子配体1(PD-L1)在乳腺癌中的表达及其与临床病理参数的关系和预后分析 被引量:8

Expression of PD-L1 in Breast Cancer and Its Clinicopathological Parameters and Prognosis
暂未订购
导出
摘要 目的系统比较三阴性乳腺癌、非三阴性乳腺癌和癌旁组织的PD-L1表达及其与临床病理参数的相关性,同时探讨PD-L1的表达与不同类型乳腺癌的生存关系及预测预后价值。方法选取经术后病理确诊为乳腺癌的患者的蜡块及癌旁组织,采用免疫组化方法检测乳腺癌及癌旁组织的PD-L1表达,并分析PD-L1表达与临床病理参数的关系及预后分析。结果 PD-L1在乳腺癌中阳性表达率为24. 5%,在三阴性乳腺癌中阳性表达率为36%。PD-L1表达与阳性淋巴结个数、TNM分期呈正相关,与ER、PR状态呈负相关,与手法方式及分子分型相关。总生存期与阳性淋巴结个数、肿瘤大小、TNM分期、PD-L1表达率呈负相关,与ER、PR状态呈正相关。结论 PD-L1在不同类型乳腺癌中表达存在差异,三阴性乳腺癌中PD-L1表达明显高于其他类型乳腺癌,且PD-L1是影响乳腺癌患者生存的独立不良预后因素。 Objective To compare the expression of PD-L1 in triple-negative breast cancer,non-triple-negative breast cancer and paracancerous tissues systematically and its correlation with clinicopathological parameters,and to explore the relationship between the expression of PD-L1 and the survival of different types of breast cancer and prognosis.Methods Selected breast cancer patients after pathological diagnosis.To analyze the relationship between PD-L1 and clinical pathological parameters and prognosis,we detected the expression of PD-L1 in breast cancer tissues and paracancerous tissues by immunohistochemistry.Results PD-L1 was expressed in 24.5%breast cancer and in 36%triple-negative breast cancer.PD-L1 expression was positively associated with TNM staging,more positive lymph node number,as well as negative ER and PR status.It was associated with molecular typing and surgical methods.The Overall survival was negatively associated with tumor size,TNM staging,PD-L1 expression,more positive lymph node number,as well as positive ER and PR status.Conclusion PD-L1 expressed differently in different types of breast cancer.The expression of PD-L1 in the triple-negative breast cancer is significantly higher than other types of breast cancer.The expression of PD-L1 in breast cancer is an independent negative prognostic factor.
作者 邱志敏 王美鑑 付爱荣 王雅琦 董涵之 傅颖媛 QIU Zhimin;WANG Meijian;FU Airong(Jiangxi Cancer Hospital,Nanchang,330029)
出处 《实用癌症杂志》 2018年第11期1784-1787,1790,共5页 The Practical Journal of Cancer
基金 江西省卫生计生委科技计划(编号:20185361)
关键词 乳腺癌 程序性死亡因子配体1 预后 Breast cancer Programmed death ligand 1 Prognosis
  • 相关文献

参考文献2

二级参考文献6

共引文献33

同被引文献87

引证文献8

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部